Donate Help Contact The AHA Sign In Home
American Heart Association
Arteriosclerosis, Thrombosis, and Vascular Biology
Search: search_blue_button Advanced Search
Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1156-1162
Published online before print February 23, 2006, doi: 10.1161/01.ATV.0000214960.85469.68
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
26/5/1156    most recent
01.ATV.0000214960.85469.68v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Liu, S. X.
Right arrow Articles by Zhang, X.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Liu, S. X.
Right arrow Articles by Zhang, X.
Related Collections
Right arrow Risk Factors
Right arrow Mechanism of atherosclerosis/growth factors
(Arteriosclerosis, Thrombosis, and Vascular Biology. 2006;26:1156.)
© 2006 American Heart Association, Inc.


Atherosclerosis and Lipoproteins

Advanced Oxidation Protein Products Accelerate Atherosclerosis Through Promoting Oxidative Stress and Inflammation

Shang Xi Liu; Fan Fan Hou; Zhi Jian Guo; Ryoji Nagai; Wei Ru Zhang; Zhi Qiang Liu; Zhan Mei Zhou; Mei Zhou; Di Xie; Guo Bao Wang; Xun Zhang

From the Division of Nephrology (S.X.L., F.F.H., Z.J.G., W.R.Z., Z.Q.L., Z.M.Z., M.Z., D.X., G.B.W., X.Z.), Nanfang Hospital, Southern Medical University, Guangzhou, PR China; and the Department of Medical Biochemistry (R.N.), Graduate School of Medical and Pharmaceutical Sciences, Kumamoto University.

Correspondence to Dr Fan-Fan Hou, Division of Nephrology, Nanfang Hospital, Southern Medical University, 1838 North Guangzhou Avenue, Guangzhou 510515, PR China. E-mail ffhou{at}public.guangzhou.gd.cn

Objective— Increased level of plasma advanced oxidation protein products (AOPPs) has been found in patients with uremia and nonuremic subjects with coronary artery disease. This study was conducted to test the hypothesis that AOPPs play a causal role in atherosclerosis.

Methods and Results— Hypercholesterolemic (0.5% wt/wt diet) or normal rabbits received either repeated intravenous injections of AOPPs modified rabbit serum albumin (AOPPs-RSA) or unmodified RSA for 8 weeks. Compared with RSA- or vehicle-treated hypercholesterolemic rabbits, AOPPs-RSA–treated animals displayed increased atherosclerotic plaque area oxidized low-density lipoprotein (oxLDL) deposition, macrophage infiltration, and smooth muscle cell proliferation. Aortic sections from AOPPs-RSA–treated normal rabbits showed significant focal intima proliferation and mild Oil-Red-O staining lipid deposition in the affected areas, a phenomenon not observed in the RSA- or vehicle-treated controls. Plasma AOPPs levels in AOPPs-treated groups significantly increased in both hypercholesterolemic and normal rabbits compared with their relevant controls. Close correlations were found between plasma levels of AOPPs and the parameters of oxidative stress, eg, oxLDL and thiobarbituric acid reactive substances levels, or glutathione peroxidase activity. A highly significant correlation was also observed between plasma AOPPs and tumor necrosis factor (TNF)-{alpha} levels.

Conclusions— This study provides in vivo evidence for a causal relationship between chronic AOPPs accumulation and atherosclerosis.

Increased levels of plasma advanced oxidation protein products (AOPPs) have been found in patients with uremia and in subjects with coronary artery disease. This study investigated the role of AOPPs in the development of atherosclerosis. The results demonstrated that AOPPs accelerate atherosclerosis via enhancing oxidative stress and inflammation.


Key Words: advanced oxidation protein products • atherosclerosis • hypercholesterolemia • inflammation • oxidative stress




This article has been cited by other articles:


Home page
Circ. Res.Home page
G. Marsche, S. Frank, A. Hrzenjak, M. Holzer, S. Dirnberger, C. Wadsack, H. Scharnagl, T. Stojakovic, A. Heinemann, and K. Oettl
Plasma-Advanced Oxidation Protein Products Are Potent High-Density Lipoprotein Receptor Antagonists In Vivo
Circ. Res., March 27, 2009; 104(6): 750 - 757.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
X. F. Wei, Q. G. Zhou, F. F. Hou, B. Y. Liu, and M. Liang
Advanced oxidation protein products induce mesangial cell perturbation through PKC-dependent activation of NADPH oxidase
Am J Physiol Renal Physiol, February 1, 2009; 296(2): F427 - F437.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
Y. Iwao, K. Nakajou, R. Nagai, K. Kitamura, M. Anraku, T. Maruyama, and M. Otagiri
CD36 is one of important receptors promoting renal tubular injury by advanced oxidation protein products
Am J Physiol Renal Physiol, December 1, 2008; 295(6): F1871 - F1880.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
X. Y. Shi, F. F. Hou, H. X. Niu, G. B. Wang, D. Xie, Z. J. Guo, Z. M. Zhou, F. Yang, J. W. Tian, and X. Zhang
Advanced Oxidation Protein Products Promote Inflammation in Diabetic Kidney through Activation of Renal Nicotinamide Adenine Dinucleotide Phosphate Oxidase
Endocrinology, April 1, 2008; 149(4): 1829 - 1839.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
G. Marsche, B. Weigle, W. Sattler, and E. Malle
Soluble RAGE blocks scavenger receptor CD36-mediated uptake of hypochlorite-modified low-density lipoprotein
FASEB J, October 1, 2007; 21(12): 3075 - 3082.
[Abstract] [Full Text] [PDF]


Home page
ANGIOLOGYHome page
E. Papalambros, F. Sigala, S. Georgopoulos, K. I. Paraskevas, I. Andreadou, X. Menenakos, P. Sigalas, A. L. Papalambros, G. Vourliotakis, A. Giannopoulos, et al.
Malondialdehyde as an Indicator of Oxidative Stress During Abdominal Aortic Aneurysm Repair
Angiology, September 1, 2007; 58(4): 477 - 482.
[Abstract] [PDF]


Home page
Epidemiol RevHome page
S. Musaad and E. N. Haynes
Biomarkers of Obesity and Subsequent Cardiovascular Events
Epidemiol. Rev., May 10, 2007; (2007) mxm005v1.
[Abstract] [Full Text] [PDF]


Home page
FASEB J.Home page
G. Marsche, M. Semlitsch, A. Hammer, S. Frank, B. Weigle, N. Demling, K. Schmidt, W. Windischhofer, G. Waeg, W. Sattler, et al.
Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway
FASEB J, April 1, 2007; 21(4): 1145 - 1152.
[Abstract] [Full Text] [PDF]


Home page
J. Am. Soc. Nephrol.Home page
H. Y. Li, F. F. Hou, X. Zhang, P. Y. Chen, S. X. Liu, J. X. Feng, Z. Q. Liu, Y. X. Shan, G. B. Wang, Z. M. Zhou, et al.
Advanced Oxidation Protein Products Accelerate Renal Fibrosis in a Remnant Kidney Model
J. Am. Soc. Nephrol., February 1, 2007; 18(2): 528 - 538.
[Abstract] [Full Text] [PDF]


Home page
Nephrol Dial TransplantHome page
I. Nikolov, N. Joki, T. Drueke, and Z. Massy
Beyond phosphate--role of uraemic toxins in cardiovascular calcification
Nephrol. Dial. Transplant., December 1, 2006; 21(12): 3354 - 3357.
[Full Text] [PDF]